



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$40.58
Change (%)	▲ 0.28 (0.69%)
Volume	319,783
52 Week Low	\$24.47
Market Cap	\$1,672,365,389
Rolling EPS	1.39
PE Ratio	28.9524
Shares Outstanding	41,211,567

Data as of 10/20/17 4:02 p.m. ET



Recent Headlines & Events

10/19/17

Emergent BioSolutions to Release Third Quarter and Nine Months 2017 Financial Results and Conduct a Conference Call on November 2, 2017

10/06/17

Emergent BioSolutions Completes Acquisition of ACAM2000® Business From Sanofi

10/04/17

Emergent BioSolutions Awarded U.S. Department of State Contract Valued at Up to \$25 Million to Supply Nerve Agent Antidote Auto-Injector

Date	Title
11/02/17 5:00 p.m. ET	Q3 2017 Emergent BioSolutions Inc. Earnings Conference Call
11/15/17 through 11/16/17	Emergent BioSolutions Inc. at Three Part Advisors Southwest IDEAS Investor Conference
12/04/17	Emergent BioSolutions Inc. at Singular Best of the Uncovered 12th Annual Conference

SEC Filings

Filing Date	Form
10/06/17	8-K
10/03/17	8-K
10/02/17	8-K
09/29/17	4

Data provided by Nasdaq. Minimum 15 minutes delayed.

Primary IR Contact

Robert G. Burrows
Vice President,
Investor Relations
Emergent BioSolutions Inc.
Phone: (240) 631 3280
Fax: (240) 413-1917
E-mail: burrowsr@ebsi.com